share_log

Halozyme Therapeutics Q4 EPS $0.50 Misses $0.53 Estimate, Sales $121.70M Beat $120.16M Estimate

Halozyme Therapeutics Q4 EPS $0.50 Misses $0.53 Estimate, Sales $121.70M Beat $120.16M Estimate

Halozyme Treeutics第四季度每股收益0.50美元低于0.53美元预期,销售额1.217亿美元超过1.2016亿美元预期
Benzinga Real-time News ·  2021/02/24 05:02

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $0.50 per share which missed the analyst consensus estimate of $0.53 by 5.66 percent. This is a 308.33 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $121.70 million which beat the analyst consensus estimate of $120.16 million by 1.28 percent. This is a 126.78 percent increase over sales of $53.66 million the same period last year.

卤酶治疗公司(纳斯达克:光晕)公布季度每股收益为0.50美元,低于分析师普遍预期的0.53美元5.66%。这比去年同期每股亏损0.24美元增加了308.33%。该公司公布季度销售额为1.217亿美元,比分析师普遍预期的1.2016亿美元高出1.28%。这比去年同期5,366万美元的销售额增长了126.78%。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发